# The capital already moved on Alzheimer amyloid drugs. A new review says the science confirms it. - Date: 2026-04-16 - Category: Biotech & Life Sciences A Cochrane meta-analysis of 17 trials and 20,342 patients finds Alzheimer amyloid drugs produce no clinically meaningful benefit while raising brain swelling risk. Pharma was already moving capital to tau and inflammation targets before the review dropped. ---